---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Diagnosis"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Diagnosis. Topics: Histopathologic diagnosis; College of American Pathologists 2025 guideline update; HPV testing of oropharyngeal carcinoma by p16 immunohistochemistry; No routine HPV testing of oral cavity, laryngeal, and hypopharyngeal carcinoma; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/diagnosis"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Histopathologic diagnosis

> “The diagnosis of HNSCC can usually be made on the basis of routine histopathology with haemotoxylin and eosin staining.”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.5-2"></a>

### College of American Pathologists 2025 guideline update

> “Seven strong recommendations, 4 conditional recommendations, and 5 good practice statements are offered in the guideline update.”

Source: [Lewis et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40126379/)

<a id="topic-2.2.1.5-3"></a>

### HPV testing of oropharyngeal carcinoma by p16 immunohistochemistry

> “Recommendation 2. For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC. In certain scenarios HPV-specific testing should be performed: (1) in geographic regions with a low prevalence of HR-HPV–associated OPSCC; (2) when p16 IHC is equivocal (50%–70% staining or when staining is extensive but weak); (3) when there is a discrepancy between p16 IHC and morphology; (4) for large, multisite tumors overlapping the oropharynx; (5) when specimens are from a non-tonsillar, non–base of tongue oropharyngeal site; and (6) when required by clinical trials.”
> “For an OPSCC with classic characteristics, p16 IHC remains the optimal option for HR-HPV testing.”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-4"></a>

### No routine HPV testing of oral cavity, laryngeal, and hypopharyngeal carcinoma

> “Recommendation 8. Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.”
> “Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-5"></a>

### HPV-specific test methods

> “Recommendation 12. For HPV-specific testing, pathologists should use tests that exhibit optimal performance characteristics—such as RNA-ISH or DNA PCR—and have adequate coverage of non–HPV 16 high-risk types. DNA-ISH is not recommended.”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-6"></a>

### FDA-approved PD-L1 companion diagnostic for pembrolizumab in HNSCC

| Field | Quoted entry |
| --- | --- |
| Diagnostic name | “PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)” |
| Indication and specimen | “Head and Neck Squamous Cell Carcinoma (HNSCC) - Tissue” |
| Drug | “Keytruda (pembrolizumab) BLA 125514” |
| Biomarker | “PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]” |
| Approval | “P150013/S014 (06/10/2019)” |

Source: [FDA List of Cleared or Approved Companion Diagnostic Devices (2026)](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)

<a id="topic-2.2.1.5-7"></a>

### PD-L1 and p16 assessment in the first-line pembrolizumab registration trial

> “Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).”
> “A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.5-8"></a>

### PD-L1 testing patterns in U.S. recurrent or metastatic HNSCC

> “Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.”

Source: [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)

> “Evidence of PD-L1 testing of any kind was identified for 71.7% of the study population, and a CPS test result was available for 352 individuals (54.5%).”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
